ORTHOCELL LIMITED — Capital/Financing Update 2018

Oct 17, 2018

==> picture [594 x 111] intentionally omitted <==

Orthocell presents successful CelGro® study results at key European Conference

• Successful CelGro® bone repair study results presented at the 27th European Association for Osseointegration (EAO) Annual Scientific Meeting attended by more than 2,900 delegates

• Study results demonstrate CelGro® results in up to 26% better quality newly formed bone when compared to market leading comparative product

• CelGro® is approved for use in Europe and gathering s ignificant market traction

• Represents a key milestone in Orthocell’s KOL-led commercialisation strategy, to build product awareness and educate surgeons of the benefits of using superior membranes

Perth, Australia; 18[th ] October 2018 : Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell”, or the “Company”) is pleased to report the successful CelGro® bone repair study results were presented at the 27[th] European Association for Osseointegration (EAO) Annual Scientific Meeting held recently in Vienna. The EAO Annual Scientific Meeting is the industry leading global dental congress and was attended by more than 2,900 delegates and 1,000 trade representatives.

CelGro® is approved for use in Europe (CE Mark) in a variety of dental bone and soft tissue regeneration procedures and has demonstrated superior clinical performance for dental bone defect repair when compared to the market leading product. The EAO Annual Scientific Meeting provided Orthocell and its Key Opinion Leaders (KOLs) with an opportunity to present the successful CelGro® bone repair clinical data and have direct interaction with clinicians, distributors and potential partners. This represents a key milestone in Orthocell’s commercialisation strategy, leading to greater awareness and recognition of Orthocell’s superior collagen membrane for dental bone defect repair.

Orthocell Managing Director Paul Anderson said: “This is an important step in the dissemination of this exciting clinical data to the wider European dental community, indicating CelGro® results in high quality bone repair during dental implant placement. The event forms a valuable part of our wider commercialisation strategy. Dentists and oral surgeons demand innovative devices that improve patient outcomes and Orthocell is making significant progress in positioning CelGro® as the best in class collagen membrane for bone repair.”

Professor Ming Hao Zheng, from the University of Western Australia and Orthocell’s Chief Scientific Officer presented the successful CelGro® bone repair study results highlighting the membranes superior handling qualities and bone repair outcomes when used for Guided Bone Regeneration (GBR) treatment to preserve or restore bone volume required for successful functional and aesthetic outcomes in dental implant procedures. The clinical data poster can be viewed at : - - https://www.orthocell.com.au/new page 2/

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au

==> picture [594 x 111] intentionally omitted <==

Professor Zheng said: “Underpinned by its tissue integration qualities, biocompatibility and superior handling characteristics, CelGro® has demonstrated the ability to improve bone quality (up to 26% better quality newly formed bone) compared to the market leading comparative product.

The theme of the programme was “Dreams and reality in implant dentistry” and the boundaries between what is clinically possible, emerging techniques and patient expectations in the field of dental implants. Advances in technology are changing the way in which oral surgeons plan and execute dental implant solutions enabling a personalised approach to treatment plans targeting improvements in patient outcomes.

The EAO Annual Scientific Meeting provided an opportunity to build awareness of the potential patient benefits provided by best in class products such as CelGro®. Orthocell is well positioned to establish CelGro® as the best class membrane for bone repair in this significant and growing market.

For more information, please contact:

General enquiries

Investor enquiries

Media enquiries

Paul Anderson Joel Seah Haley Chartres Orthocell Limited Vesparum Capital Hales[2 ] Communications Managing Director P: +61 8 9360 2888 P: +61 3 8582 4800 P: +61 423 139 163 E: paulanderson@orthocell.com.au E: orthocell@vesparum.com E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for market authorisation in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd =

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au